TITLE: Real-world effectiveness of hydroxychloroquine, azithromycin, and ivermectin among

hospitalized COVID-19 patients: results of a target trial emulation using observational data from a

nationwide healthcare system in Peru.

Brief Title: Target trial emulation of hydroxychloroquine, azithromycin, and ivermectin

effectiveness.

#### **Authors:**

Percy Soto-Becerra, MD<sup>1</sup>

Carlos Culquichicón, MD<sup>1</sup>

Yamilee Hurtado-Roca, MD, PhD1

Roger V. Araujo-Castillo, MD<sup>1</sup>

#### **Affiliations:**

1) Instituto de Evaluación de Tecnologías en Salud e Investigación – IETSI, EsSalud

Jiron Domingo Cueto 120, Eight floor, Jesus Maria

Lima 15073, Peru.

### **Corresponding author:**

Roger V. Araujo-Castillo

Av. Arenales 1302, office 310. Jesus Maria, Lima 15073, Peru.

Phone: 51(1) 265-6000 - Extension 1955

E-mail: roger.araujo@essalud.gob.pe

#### **ABSTRACT**

**Introduction:** Peru is one of the most impacted countries due to COVID-19. Given the authorized use of hydroxychloroquine (HCQ), azithromycin (AZIT), and ivermectin (IVM), we aimed to evaluate their effectiveness alone or combined to reduce mortality among COVID-19 hospitalized patients without life-threatening illness.

**Methods:** Retrospective cohort emulating a target trial, using nationwide data of mid- and high-level hospitals from the Peruvian Social Health Insurance 01/April/2020–19/July/2020. Patients 18 yo and above with PCR-confirmed SARS-CoV-2, and no life-threatening illness at admission were included. Five treatment groups (HCQ alone, IVM alone, AZIT alone, HCQ+AZIT, and IVM+AZIT within 48 hours of admission) were compared with standard of care alone. Primary outcome was all-cause mortality rate; secondary outcomes were all-cause death and/or ICU transfer, and all-cause death and/or oxygen prescription. Analyses were adjusted using inverse probability of treatment weighting. Propensity scores were estimated using machine learning boosting models. Weighted hazard ratios (wHR) were calculated using Cox regression.

**Results:** Among 5683 patients, 200 received HCT, 203 IVM, 1600 AZIT, 692 HCQ+AZIT, 358 IVM+AZIT, and 2630 standard of care. HCQ+AZIT was associated with 84% higher all-cause death hazard compared to standard care (wHR=1.84, 95%CI 1.12-3.02). Consistently, HCQ+AZIT was also associated with higher death and/or ICU transfer (wHR=1.49, 95%CI 1.01-2.19), and death and/or oxygen prescription (wHR=1.70, 95%CI 1.07-2.69). HCQ only showed higher death and/or oxygen prescription hazard. No effect was found for AZIT or IVM+AZIT.

**Conclusions:** Our study reported no beneficial effects of hydroxychloroquine, ivermectin, azithromycin. The HCQ+AZIT treatment seems to increase risk for all-cause death.

Funding: Instituto de Evaluación de Tecnologías en Salud e Investigación – IETSI, EsSalud

**KEYWORDS:** COVID-19 drug treatment; Hydroxychloroquine; Azithromycin; Ivermectin; Machine Learning; Peru.

#### **INTRODUCTION**

The coronavirus disease 2019 (COVID-19) imposed a major global challenge given its rapid transmission worldwide and high mortality (1, 2). No pharmacological treatment have demonstrated effectiveness to control the SARS-CoV-2 infection or improving clinical outcomes, worsening the current sanitary emergency, especially for low-middle income countries (3). Traditionally, the development of any specific drug might take several years. However, given the rapid spread of the pandemic, several existing drugs have been repurposed based on in-vitro studies or low-quality evidence. Consequently, there has been extensive efforts on investigating the efficacy and effectiveness of several pharmacological treatments using randomized clinical trials as well as observational studies (4).

Currently, only dexamethasone has demonstrated benefit to reduce all-cause mortality and mechanical ventilation use; meanwhile, remdesivir seems to reduce symptoms duration and occurrence of severe adverse events (5). On the other hand, some emergently repurposed treatments have consistently demonstrated no benefits on all-cause mortality, including hydroxychloroquine with or without azithromycin, lopinavir-ritonavir, and convalescent plasma (5). Ivermectin has only demonstrated efficacy in laboratory conditions, but not evidence has yet reported on hospitalized patients with COVID-19 (6). Despite many of these studies had serious limitations, these drugs continue to being used in different health systems worldwide, and some of them have even been tested for pre-exposure prophylaxis finding the same unsuccessful results (7).

Peru has been greatly impacted by the pandemic. By October 5, 2020, it is the sixth country by number of reported cases (828 169 cases), and has the highest mortality rate worldwide (101.94 deaths per 100 000 inhabitants) (8, 9). The urgent need to address this national crisis, drove the Peruvian Ministry of Health to authorize the use of hydroxychloroquine with or without azithromycin for COVID-19 patients, later adding oral ivermectin alone or in combination with the other drugs (10, 11). Given the authorized use of these drugs, and the availability of electronic health records in the nationwide Peruvian Social Health Insurance (EsSalud), we intended to use this real-world data to emulate a randomized controlled clinical trial using propensity score weighting (12, 13). In this way, the biases traditionally associated with observational studies might be minimized producing more realistic estimates of effectiveness (14), especially when combined with novel machine-learning algorithms. Thus, our study aimed to evaluate the effectiveness of hydroxychloroquine, azithromycin, and ivermectin alone or combined, to prevent all-cause deaths

in hospitalized patients with COVID-19 but without life-threatening illness. Secondarily, we evaluated two composite outcomes: death and/or intense care unit (ICU) transfer, and death and/or oxygen prescription.

#### **METHODS**

### Study design and population

We conducted a retrospective cohort analyzing data obtained from electronic records of patients hospitalized with COVID-19 in mid- and high-level complexity hospitals from the Peruvian Social Security Health System (EsSalud). We emulated a target trial to obtain robust estimates of clinical effectiveness for hydroxychloroquine/chloroquine, azithromycin, ivermectin, alone or combined, on relevant clinical outcomes (12, 15). We retrieved anonymized data from EsSalud central data system (16) using the International Classification of Disease Tenth (ICD-10) codes for COVID-19, as defined by the Pan-American Health Organization (17).

We included patients hospitalized between April 1 and July 19, 2020 with the following criteria: 18 years old or above; confirmed SARS-CoV-2 infection by RT-qPCR; clinical manifestations compatible with non-life-threatening disease at admission (no acute respiratory failure, no sepsis or septic shock, no acute respiratory distress syndrome [ARDS], no acute pulmonary edema, no disseminated intravascular coagulation [DIC]). We excluded patients who were prescribed oxygen at admission since it is part of one of the outcomes. We also excluded patients with: self-report of pregnancy at admission; discharge, ICU admission, or death within 24 hours of admission; prescription of other experimental drugs (tocilizumab, lopinavir-ritonavir or remdesivir) within 48 hours of admission; self-reported treatment of hydroxychloroquine for rheumatological diseases; and patients with records of having received any of the studied drugs before admission.

## Treatment strategies

The standard of care was defined as antipyretics, hydration, monitorization and basic supportive care. We compared it with five treatment arms, defined as the standard of care plus: hydroxychloroquine/chloroquine alone (HCQ), ivermectin alone (IVM), azithromycin alone (AZIT), hydroxychloroquine/chloroquine plus azithromycin (HCQ+AZIT), and ivermectin plus azithromycin (IVM+AZIT) at doses recommended by the Peruvian Ministry of Health (10, 11). The decision to administer any of these treatments depended on the treating physician's own criteria

guided by the Ministry of Health recommendations, which varied over time (10, 11). Thus, there was an expected heterogeneity of regimens across different services, hospitals, and even month of hospitalization.

We allowed a grace period of 48 hours to initiate therapy to assess a more realistic clinical question: what is the effectiveness of initiating therapy compared to only receiving standard care within 48 hours of hospitalization? Hence, patients who received any of the treatment regimens after 48 hours of hospitalization were assigned to the control group, similar to an intention-to-treat analysis. As mentioned before, we only excluded patients who developed any of the outcomes within 24 hours of admission; therefore, some included patients could have developed an outcome before being assigned to any group due to the grace period (48 hours). Given that these patients could have potentially been assigned to any group, they were randomly distributed between the control and treatment groups to avoid time-dependent bias due to inappropriate exclusion or treatment assignment (12).

### Start, end of follow-up and outcomes

The onset of follow-up or time zero for each patient was the date of hospitalization. The end of the follow-up was the date of occurrence of any outcome (death, death and/or transfer to ICU, death and/or oxygen prescription), discharge, or end of follow-up by July 19, 2020. The primary outcome was all-cause in-hospital death, and the secondary composite outcomes were all-cause in-hospital death and/or transfer to ICU, and all-cause in-hospital death and/or oxygen prescription.

#### Strategy for emulating random assignments

In order to emulate the random assignments of a target trial, we used a propensity score weighting for multivalued treatments employing a machine-learning approach that let us calculate balanced differences for each control and treatment groups according to their baseline covariates (18, 19). A propensity score (PS) estimates the subject probability of receiving a certain treatment given their pre-treatment characteristics, but can also be used to create weights that allows robust estimations of causal effects in observational studies (20). Moreover, we used generalized boosting models (GBM) based on machine-learning algorithms to determine which baseline covariates should be included, and to estimate the PS (15, 21). The GBM is a non-parametric approach that fits classification trees using large and non-parsimonious number of pre-treatment covariates. This improves traditional PS estimation (22) because it minimizes bias from model misspecification commonly obtained by incorrect parametric model assumptions (23), and works well with missing

data (22). We trained 5000 classification trees setting the following parameters: bag fraction of 1, shrinkage factor of 0.01, test all two- and three-covariates interactions (24), and standardized mean minimization as the stop method to select optimal balance. The PS obtained were transformed into propensity score odds weights (PSW) used to estimate the average assignment effect on treated subjects (25, 26). This method sets the PSW to 1 for each treatment group participants and calculates the PSW for standard care group using the odds in the reference group (PSW = propensity score/(1-propensity score)) (26).

All the variables included in the propensity score model were selected beforehand based on expert knowledge about COVID-19, or because they were considered possible confounders, or were prognostically relevant to the outcomes (18). We did not include variables theoretically associated only with treatment assignment, but not with outcome, to avoid power reduction and/or bias amplification (18, 27). The baseline covariates were: age; sex; month of admission; healthcare center location (Capital, North, South, Centre, Rainforest); Charlson's index at hospital admission; known comorbidities in the first 48 hours (myocardial infarct/chronic heart failure/peripheral vascular disease; chronic lung disease; mild/severe liver disease; uncomplicated/complicated diabetes mellitus; cancer, stroke/dementia/paralysis; chronic kidney disease; metabolic disease; peptic ulcer disease; HIV; uncomplicated/complicated hypertension); emergency care before admission; antibiotics (other than azithromycin) used within 48 hours of admission; previous use of angiotensin-converting enzyme inhibitors/angiotensin-II receptor antagonists; pneumonia diagnosed within 48 hours of admission. We assessed the overlap of propensity score distributions between the control group and each treatment arm to verify the common support assumption. The balance was assessed using standardized mean differences for numerical covariates, and row differences for categorical variables. We considered a threshold of 10% as indicative of meaningful imbalance (18). During balance optimization, we remained blinded to the outcome results of the study. Propensity score estimation was performed using the function mnps from the Twang package (24), and covariate balance was assessed using *cobalt* (28), both in R version 4.0.2 (29) for MS Windows Pro 10x64 bits.

#### Statistical analysis

We reported baseline characteristics of the control and treatment groups and 30-days cumulative incidence estimated with the Kaplan-Meier method. Comparisons of time-to-event outcomes between treatment groups were done using weighted Kaplan-Meier (KM) survival curves. We estimated unweighted (uHR) and propensity score weighted hazard ratios (wHR) using Cox

proportional hazards regression to assess effectiveness. To additionally control for residual confounding, we estimated weighted HR with doubly robust adjustment (drwHR) by performing a multivariable and weighted Cox model that incorporated all the covariates used to create the propensity score. We also performed a Bonferroni adjustment of the p-values and the 95% confidence intervals (CI) dividing the type-I-error rate of 5% by five comparisons. All survival analyses were weighted by PSWs in Stata SE version 16.1 for Windows Pro 10 x64 bits (30).

**Ethics** 

This study was classified as minimal risk for participants. To maintain the privacy of the patients, EsSalud's informatics office anonymized all datasets before transfer to researchers. The protocol was approved by EsSalud's Institutional Review Board for COVID studies (91-SGRyGIS-DIS-IETSI-ESSALUD-2020) and was also registered in the Peruvian Health Research Projects repository (PRISA, by its acronym in Spanish) with ID EI-1243 (31).

RESULTS

We included 5683 patients from 72 healthcare centers distributed in 28 health networks at national level. Of whom 200 received HCQ, 203 IVM, 1600 AZIT, 692 HCQ+AZIT, 358 IVM+AZIT, and 2630 received standard of care (Figure 1). The 36.8% (n = 2091) of participants were women, and the age ranged from 18 to 104 years old with a mean of 59.4 years old (SD 16.3 years old). Table 1 describes the baseline characteristics of each arm of the study population.

Propensity score model development

Propensity scores showed well overlapping in the region of common support between treatment groups versus control group (>95%) (SM Figure 1). Before inverse probability of treatment weighting, twelve of 30 baseline covariates had high misbalance (>10% standardized mean difference) across different groups. After applying the weighting, only one of the 30 baseline covariates (age) remained imbalanced (>10% standardized mean difference) (Figure 2).

Follow-up and outcomes

The median follow-up for overall survival was 7 days (9 for HCQ, 8 for IVM, 8 for AZIT, 9 for HCQ+AZIT, 8 for IVM+AZIT). At the end of follow-up, 1072 out of 5683 (18.9%) patients had died: 49 (15.3%) in HCQ, 47 (24.5%) in IVM, 325 (23.2%) in AZIT, 165 (23.5%) in HCQ+AZIT,

6

and 85 (23.5%) in IVM+AZIT. Figure 3 shows weighted KM survival curves for the primary outcome, while SM Figure 2 and SM Figure 3 show weighted KM survival curves for secondary outcomes.

Thirty-day cumulative incidence, plus unweighted and weighted hazard rates are shown in Table 2. After using the inverse probability weighting approach, we observed that HCQ+AZIT was associated with 84% higher all-cause death hazard compared to standard care (wHR = 1.84; 95%CI 1.12-3.02). Consistently, HCQ+AZIT was associated with higher all-cause death and/or ICU transfer hazard (wHR = 1.49, 95% CI: 1.01-2.19) and higher all-cause death and/or oxygen prescription hazard (wHR = 1.70, 95% CI: 1.07-2.69). Except for survival without transfer to ICU, these results were consistent even after doing double-robust adjustment to reduce residual confounding in the sensitivity analysis (see SM Table 1).

We found inconsistent results regarding the estimated effect of HCQ using weighted analysis. It did not show association with the primary outcome or with death/ICU transfer, but with all-cause death and/or oxygen prescription, revealing a 77% higher hazard (wHR = 1.77, 95% CI: 1.01-3.11). The double-robust adjustment sensitivity analysis showed that HCQ treatment was associated with higher all-death hazard (drwHR = 2.08, 95% CI: 1.12-3.86), all-cause death and/or ICU transfer hazard (drwHR = 1.69, 95% CI: 1.04-2.76), and all-cause death and/or oxygen prescription hazard (drwHR = 2.13, 95% CI: 1.20-3.77) compared to the control group.

We observed that IVM was associated with higher all-cause death and/or ICU transfer hazard in the weighted analysis (wHR = 1.58, 95% CI:1.11-2.25) but not with the other two outcomes. Surprisingly, this finding persisted in the sensibility analysis (drwHR = 1.60, 95% CI: 1.12-2.27). On the other hand, we did not find effect on all-cause deaths or the composite endpoints for neither AZIT nor IVM+AZIT in all weighted (Table 2) and double-adjusted weighted analyses (SM Table 1).

# **DISCUSSION**

This is the first study in Latin America, a region widely impacted by the pandemic, emulating a clinical trial based on observational data comparing different drug treatments for COVID-19. Using a database based on thousands of electronic clinical records, it was possible to replicate conditions

7

of a clinical trial under real-world conditions for several drugs prescribed during the pandemic. This study also employed novel statistical tools to emulate adequate randomization of the patients. Not only a propensity score weighting was used to balance the control and intervention groups, but they were obtained through generalized boosting models based on repeated decision trees. The resulting models for our main outcome, all-cause in-hospital deaths, and for the two secondary composite outcomes, showed no benefit from any of the treatment arms compared with standard care. There was even a consistent increase of risk developing the outcome with the hydroxychloroquine and azithromycin combination. It is then possible that the drugs evaluated have no effect on hospitalized persons who are at risk or have already developed lung involvement.

## Azithromycin alone

Our study showed no effect of azithromycin alone over mortality, survival without ICU, and survival without oxygen requirement. Few published studies have compared azithromycin alone, versus standard of care. Albani et al followed a cohort of 1403 patients either receiving azithromycin alone, hydroxychloroquine alone, the combination of both, or none of them. Using propensity score weighting, they found that azithromycin alone was associated with lower mortality (OR 0.60; 95%CI 0.42-0.85) compared to no treatment. Guerin et al (32) compared 34 patients on azithromycin alone with no treatment, finding reduction in days to achieve clinical recovery (12.9) vs 25.8; p=0.015). On the other hand, Geleris et al (33) analyzed a large single-center cohort in NYC using propensity score matching to evaluate hydroxychloroquine, but also azithromycin alone vs standard of care, finding no benefit for death and/or ICU transfer (HR 1.03; 95%CI 0.81-1.31). Arshad et al (34) also evaluated azithromycin alone as a secondary aim in their multicenter, retrospective, propensity score matched observational study, finding no effect (HR 1.05; 95%CI 0.68-1.62). Rodriguez-Molinero et al followed a cohort of 239 patients treated with azithromycin alone (35), matching 29 patients on azithromycin alone with an equal number of controls using multiple clinical and prognosis factors. They found no difference in oxygen saturation/fraction of oxygen at 48h, and a longer time to discharge in the azithromycin group. When using the unmatched whole cohort, they found no difference in any of these outcomes. In summary, the available evidence is still contradictory, but leaning on no effect.

#### Hydroxychloroquine alone

We found a slight increase of risk for death and/or oxygen requirement, but not for our primary outcome (death), or death and/or ICU transfer in our weighted models. This is consistent with the systematic review published by Fiolet et al (36) including three randomized controlled trials

(RCTs), one non-randomized trial, and 25 observational studies. They included 11932 patients on the hydroxychloroquine alone group, 8081 on the hydroxychloroquine/azithromycin group, and 12930 on the control group. They found no association of hydroxychloroquine alone with mortality with a pooled relative risk (RR) of 0.83 (95%CI 0.65-1.06) for all 17 studies and RR of 1.09 (95%CI 0.97-1.24) for the three RCTs. Among these studies, Geleris et al (33), after using propensity score matching, found no significant association between hydroxychloroquine and intubation or death (HR 1.04; 95%CI 0.82-1.32). On the other hand, hydroxychloroquine was associated with all three outcomes in our double-adjusted models. These results are in accord with the recently published RCT on hydroxychloroquine by the Recovery Collaborative Group (37). They found less probability of being discharged alive from hospital within 28 days (RR 0.90; 95%CI 0.83-0.98) with hydroxychloroquine, and a higher frequency of invasive mechanical ventilation or death (RR 1.14; 95%CI 1.03-1.27).

# Hydroxychloroquine/azithromycin combination

Noticeably, we found a consistent increase on the risk for the three outcomes among patients who received the hydroxychloroquine/azithromycin combination compared with standard of care. Similarly, the systematic review by Fiolet et al (36) found that hydroxychloroguine/azithromycin was associated with an increased mortality (RR 1.27; 95%CI 1.04-1.54) using six observational studies plus a RCT. This RCT (38), 447 patients, showed no improvement of clinical outcomes with the use of azithromycin in addition to standard of care that included hydroxychloroquine (OR 1.36; 95%CI 0.94-1.97) in severe COVID-19. Two other RCTs, not included in the Fiolet review, also showed no benefit. A Brazilian multicenter open-label RCT (39), 504 patients, found no difference on a seven-point ordinal scale at 15 days either with hydroxychloroquine alone, or in combination with azithromycin. More important, they found more episodes of QT prolongation and liver-enzyme elevation among patients receiving hydroxychloroquine, alone or with azithromycin. An open-label RCT in Iran compared 55 patients on hydroxychloroquine plus lopinavir with 56 patients who received azithromycin on top of that regimen, finding no difference in mortality (40). However, there are at least two big observational studies, which found a beneficial effect of the combination. Arshad et al (34) included 2561 patients, and found a 66% HR reduction with hydroxychloroquine, and a 71% reduction with hydroxychloroquine/azithromycin. Lauriola et al reported an observational study with 377 patients, finding a reduced in-hospital mortality with the hydroxychloroquine/azithromycin combination (HR 0.265; 95% CI 0.17-0.41) (41). Therefore, it is still not clear which is the real effect of the combination; however, there is a physio-pathological plausibility that the combination increased cardiac adverse events, affecting survival (42).

#### *Ivermectin*

Until the date of this manuscript, there are no published clinical trials or large observational studies analyzing the effect of ivermectin on patients hospitalized with COVID-19. We found no association of ivermectin with all-cause mortality or with death and/or oxygen requirement; however, a deleterious effect was found on death and/or ICU admission. The reason of this association is not immediately clear for us, given the no-effect on the other two outcomes. One possibility is the presence of residual confounding despite the propensity score matching and further model adjustments. We only found pre-printed observational studies evaluating the effectiveness of this drug. The largest series is the ICON study, USA (43). They compared 173 patients on ivermectin versus 107 under usual care. They found less mortality in the ivermectin group (OR 0.52; 95% CI 0.29-0.96) and even greater effect on the subgroup with severe pulmonary disease (OR 0.15; 95%CI 0.05-0.47). A pilot study in Iraq compared 71 patients receiving hydroxychloroquine/azithromycin with 16 patients receiving ivermectin in addition (44). They found no difference on mortality (2/71 vs 0/16), but less hospitalization time in days (13.2±0.9 vs 7.6±2.8, p<0.001). Finally, there is a descriptive study in Argentina with 167 patients and no control group. They evaluated a treatment protocol that includes ivermectin, and reported an overall mortality of 0.59%, lower than their country average (45). Therefore, our study is the largest series assessing ivermectin effect among hospitalized patients and employing an adequate comparison technique.

#### Limitations and Strengths

Despite being a trial emulation, this study still is an observational retrospective cohort. Without a random assignment, residual confounding is a possibility. To control this, we used a robust approach based on incident users, defining a significant time zero to prevent immortal time-bias, allowing a grace period inclusion, and using modern data science techniques to emulate random assignment. Especially, the machine learning approach (generalized boosting model) allow us to include many more potential confounders (~30 covariates) in the weighting model, than a conventional logistic regression would allow. This is reflected in the appropriate balance and overlapping achieved between treatment and control groups once the weighting scores were applied. Moreover, a sensitivity analysis was performed using doubly robust adjustment in the weighted Cox regression models, obtaining consistently estimates of causal effects. Despite all these robust strategies, we cannot guarantee that there is some degree of residual confusion in our study. Specifically, our finding that IVM could be associated with an increased risk of one of the

secondary outcomes, but not with the rest, could be due to residual confusion not properly controlled even after double adjustment.

Other possible limitation is the occurrence of non-registered variations of the treatment, as we relied on electronic records of drug dispensing. This process is strictly monitored and even audited; however, the system does not account for unexpected missing doses. On the other hand, it is important to highlight that our study, like an intention-to-treat approach, allows to estimate the effectiveness (effect in real conditions) of the studied drugs. This approach includes drug discontinuation or regimen modification due to adverse events, poor tolerability, or simply non-adherence. Thus, our results are a good approximation to the effectiveness of these treatments, but they do not necessarily reflect their efficacy (effect under ideal conditions). Although the studied drugs were administered based on the Peruvian Minister of Health guidelines, wide variations between different healthcare centers were expected. We are confident that our weighting strategy controlled most of the heterogeneity introduced by inter-hospital disparities; however, some residual confusion is still possible.

Despite these limitations, to the best of our knowledge, this is the first clinical trial emulation done in Latin America that assessed the real-world effectiveness of different treatments for COVID-19, and so far, the largest performed using robust methods to balance groups. Different from traditional observational studies, a clinical trial emulation allows for robust design, yielding reliable results. However, equilibrating control and intervention groups is no easy task. Since most common methods have disadvantages as sample size reduction (matching) or poor overlapping (weighting), the use of machine learning algorithms based on iterative decision trees (boosting) offers an excellent opportunity to optimize the balance between groups, maintaining stable models. Besides, the use of large observational data from electronic health records provides enough power to compare different treatment arms simultaneously, does not require the logistics of a RCT, and approximates treatment effect under real-world conditions.

### Conclusions

The results of this clinical trial emulation match the findings of previous RCTs and observational studies among hospitalized patients with COVID-19, which mostly showed no beneficial effects of hydroxychloroquine, ivermectin, azithromycin, or their combinations. Once assignation bias and possible confounders are controlled, the effect of the drugs studied is not significant, implying that any effect perceived in observational studies and case series is probably due to confounding effect

and selection bias. We even detected a consistent increase in death risk, as well as transfer to ICU and oxygen requirement, with the hydroxychloroquine/azithromycin combination. This association has been reported in other studies and clinical trials, corroborating a potentially harmful effect of this combination. However, we did not have an adequate registry of pharmacological side effects in our electronic database, to suggest adverse reactions to this combination as a path for mortality increase.

ACKNOWLEDGMENTS: We thank Engr. Pedro Vasquez, Engr. Elard Pastor and all the team

from the EsSalud's informatics office (GCTIC - Gerencia Central de Tecnologías de Información y

Comunicaciones) for extracting and structuring the anonymized data from the electronic medical

records.

AUTHORS' CONTRIBUTIONS: PSB conceived and designed the research idea, wrote the

research protocol, conceived and designed the analysis, compiled and organized the data, performed

the analysis, interpreted the data, wrote the paper, and reviewed the last version of the manuscript.

Carlos Culquichicon compiled and organized the data, performed the analysis, contributed to the

writing of the paper, and reviewed the last version of the manuscript. Yamilee Hurtado-Roca

conceived and designed the research idea, contributed with analysis tools, interpreted the results,

contributed to the writing of the paper, and reviewed the last version of the manuscript. Roger V.

Araujo-Castillo conceived and designed the research idea, designed the analysis, contributed with

analysis tools, interpreted the results, wrote the paper, and reviewed the last version of the

manuscript.

**CONFLICT OF INTEREST STATEMENTS:** All the authors declare that there is no conflict of

interest regarding the content of this study.

ROLE OF FUNDING SOURCE: The study was funded by the Instituto de Evaluacion de

Tecnologias en Salud e Investigacion - IETSI, EsSalud, Lima, Peru. No other institutions or

companies participated in the funding of this study.

**ETHICS STATEMENT:** This study has followed all the recommendations of the Declaration of

Helsinki regarding research involving human subjects. The protocol was approved by EsSalud's

13

Institutional Review Board for COVID studies.

#### **REFERENCES**

- 1. Baby K, Maity S, Mehta CH, Suresh A, Nayak UY, Nayak Y. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study. Arch Med Res. 2020.
- 2. Richman DD. Antiviral Drug Discovery To Address the COVID-19 Pandemic. mBio. 2020;11(5):e02134-20.
- 3. Yu H, Li C, Wang X, Duan J, Yang N, Xie L, et al. Techniques and strategies for the potential protein-targets discovery and active pharmaceutical molecules screening in Pandemic. Journal of Proteome Research. 2020.
- 4. Sohag AAM, Hannan MA, Rahman S, Hossain M, Hasan M, Khan MK, et al. Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review. Drug Dev Res. 2020:10.1002/ddr.21709.
- 5. Juul S, Nielsen EE, Feinberg J, Siddiqui F, Jørgensen CK, Barot E, et al. Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PLOS Medicine. 2020;17(9):e1003293.
- 6. Li N, Zhao L, Zhan X. Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. Journal of Cellular Physiology. 2020;n/a(n/a).
- 7. Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, et al. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. JAMA Internal Medicine. 2020.
- 8. Johns Hopkins University. Coronavirus resource center: COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU); 2020 [Last accessed Oct 5, 2020]. Available from: <a href="https://coronavirus.jhu.edu/map.html">https://coronavirus.jhu.edu/map.html</a>.
- 9. Johns Hopkins University. Coronavirus resource center: Mortality in the most affected countries; 2020 [Last accessed Oct 5, 2020]. Available from: https://coronavirus.jhu.edu/data/mortality.
- 10. Peruvian Ministry of Health. Prevencion, diagnostico y tratamiento de personas afectadas por COVID-19 en el Peru; 2020 [Last accessed Oct 5, 2020]. Available from: <a href="https://www.gob.pe/institucion/minsa/informes-publicaciones/473587-prevencion-diagnostico-y-tratamiento-de-personas-afectadas-por-covid-19-en-el-peru">https://www.gob.pe/institucion/minsa/informes-publicaciones/473587-prevencion-diagnostico-y-tratamiento-de-personas-afectadas-por-covid-19-en-el-peru</a>.
- 11. Peruvian Ministry of Health. Manejo ambulatorio de personas afectadas por COVID-19 en el Peru; 2020 [Last accessed Oct 5, 2020]. Available from: https://cdn.www.gob.pe/uploads/document/file/830595/RM\_375-2020-MINSA.PDF.
- 12. Hernán MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. American journal of epidemiology. 2016;183(8):758-64.

- 13. Labrecque JA, Swanson SA. Target trial emulation: teaching epidemiology and beyond. Eur J Epidemiol. 2017;32(6):473-5.
- 14. Mahévas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020;369:m1844.
- 15. Lee BK, Lessler J, Stuart EA. Improving propensity score weighting using machine learning. Statistics in medicine. 2010;29(3):337-46.
- 16. Peruvian Social Health Insurance EsSalud. EsSI EsSalud's Digital Clinical Records; 2020 [Last accessed Oct 5, 2020]. Available from: <a href="https://essi.pe/">https://essi.pe/</a>.
- 17. PAHO. Covid-19 codification with ICD-10; 2020 [Last accessed Oct 5, 2020]. Available from: <a href="https://www.paho.org/arg/index.php?option=com\_docman&view=download&alias=468-covid-cie-codigos-2020-03-25-espanol&category\_slug=documentos&Itemid=624">https://www.paho.org/arg/index.php?option=com\_docman&view=download&alias=468-covid-cie-codigos-2020-03-25-espanol&category\_slug=documentos&Itemid=624</a>.
- 18. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Statistics in medicine. 2015;34(28):3661-79.
- 19. McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Statistics in medicine. 2013;32(19):3388-414.
- 20. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011;46(3):399-424.
- 21. McCaffrey DF, Ridgeway G, Morral AR. Propensity Score Estimation with Boosted Regression for Evaluating Causal Effects in Observational Studies. Psychol Methods. 2004 Dec;9(4):403-25.
- 22. Coffman DL, Zhou J, Cai X. Comparison of methods for handling covariate missingness in propensity score estimation with a binary exposure. BMC medical research methodology. 2020;20(1):168-.
- 23. Parast L, McCaffrey DF, Burgette LF, de la Guardia FH, Golinelli D, Miles JNV, et al. Optimizing Variance-Bias Trade-off in the TWANG Package for Estimation of Propensity Scores. Health Serv Outcomes Res Methodol. 2017;17(3-4):175-97.
- 24. Ridgeway G, McCaffrey D, Morral A, Griffin BA, Burgette L, M C. Toolkit for Weighting and Analysis of Nonequivalent Groups (TWANG): CRAN; 2020 [Last accessed Oct 5, 2020]. Available from: <a href="https://cran.r-project.org/web/packages/twang/">https://cran.r-project.org/web/packages/twang/</a>.
- 25. Sato T, Matsuyama Y. Marginal Structural Models as a Tool for Standardization. Epidemiology. 2003;14(6).

- 26. Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ. 2019;367:15657.
- 27. Pearl J. Invited Commentary: Understanding Bias Amplification. American Journal of Epidemiology. 2011;174(11):1223-7.
- 28. Greifer N. Covariate Balance Tables and Plots (cobalt): CRAN; 2020 [Last accessed Oct 5, 2020]. Available from: https://cran.r-project.org/web/packages/cobalt/index.html.
- 29. R Core Team R: A language and environment for statistical computing: R Foundation for Statistical Computing; 2020 [Last accessed Oct 5, 2020]. Available from: <a href="https://www.R-project.org/">https://www.R-project.org/</a>.
- 30. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC: StataCorp 2019.
- 31. Soto-Becerra P. Efectividad Clínica Comparativa de Hidroxicloroquina en el Tratamiento de COVID-19 utilizando Datos Observacionales de Registros Clínicos Electrónicos de EsSalud.: PRISA; 2020 [Last accessed Oct 5, 2020]. Available from: <a href="https://www.ins.gob.pe/prisa/ver\_investigacion.aspx?5A53F316-F127-41D6-B894-663E9C8C5E3C">https://www.ins.gob.pe/prisa/ver\_investigacion.aspx?5A53F316-F127-41D6-B894-663E9C8C5E3C</a>.
- 32. Guérin V, Lévy P, Thomas J-L, Lardenois T, Lacrosse P, Sarrazin E, et al. Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19. AJMAH 18(7):45-5.
- 33. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. The New England journal of medicine. 2020;382(25):2411-8.
- 34. Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020;97:396-403.
- 35. Rodríguez-Molinero A, Pérez-López C, Gálvez-Barrón C, Miñarro A, Macho O, López GF, et al. Observational study of azithromycin in hospitalized patients with COVID-19. PloS one. 2020;15(9):e0238681-e.
- 36. Fiolet T, Guihur A, Rebeaud ME, Mulot M, Peiffer-Smadja N, Mahamat-Saleh Y. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2020:S1198-743X(20)30505-X.

- 37. RECOVERY Collaborative Group; Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine. 2020 Oct 8. Online ahead of print.
- 38. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. The New England journal of medicine. 2020:NEJMoa2019014.
- 39. Furtado RHM, Berwanger O, Fonseca HA, Corrêa TD, Ferraz LR, Lapa MG, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. The Lancet. 2020;396(10256):959-67.
- 40. Sekhavati E, Jafari F, SeyedAlinaghi S, Jamalimoghadamsiahkali S, Sadr S, Tabarestani M, et al. Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. International journal of antimicrobial agents. 2020;56(4):106143-.
- 41. Lauriola M, Pani A, Ippoliti G, Mortara A, Milighetti S, Mazen M, et al. Effect of combination therapy of hydroxychloroquine and azithromycin on mortality in COVID-19 patients. Clinical and Translational Science. 2020;n/a(n/a).
- 42. Alizargar J. Dangers of the Use of hydroxychloroquine and azithromycin combination in COVID-19 patients. Travel medicine and infectious disease. 2020;38:101881-.
- 43. Rajter JC, Sherman M, Fatteh N, Vogel F, Sacks J, Rajter J-J. ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19. medRxiv. 2020:2020.06.06.20124461.
- 44. Gorial FI, Mashhadani S, Sayaly HM, Dakhil BD, AlMashhadani MM, Aljabory AM, et al. Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial). medRxiv. 2020:2020.07.07.20145979.
- 45. Carvallo HE, Hirsch RR, Farinella ME. Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19. medRxiv. 2020;2020.09.10.20191619.

Table 1. Baseline characteristics of patients with COVID-19 assigned to standard care (control group), or one of the treatment groups: hydroxychloroquine alone (HCQ), ivermectin alone (IVM), azithromycin alone (AZIT), hydroxychloroquine plus azithromycin (HCQ+AZIT), or ivermectin plus azithromycin (IVM+AZIT).

Baselines covariates	Standard care	HCQ	IVM	AZIT	HCQ+AZIT	IVM+AZIT	Total
	n %	n %	n %	n %	n %	n %	n %
Total	2,630	200	203	1,600	692	358	5,683
Sex							
Female	1,128 42.9	62 31	73 36	493 30.8	220 31.8	115 32.1	2,091 36.8
Male	1,502 57.1	138 69	130 64	1,107 69.2	472 68.2	243 67.9	3,592 63.2
Mean age (SD), years	56.3 (17.2)	59.1 (14.8)	62.9 (15.2)	60.2 (15.4)	59.9 (14.4)	60.0 (15.7)	58.4 (16.3)
Healthcare center location							
Capital of Peru	1,402 53.3	111 55.5	66 32.5	864 54	317 45.8	113 31.6	2,873 50.6
East region	144 5.5	14 7	3 1.5	92 5.8	32 4.6	9 2.5	294 5.2
Centre region	268 10.2	18 9	33 16.3	286 17.9	160 23.1	130 36.3	895 15.7
North region	434 16.5	25 12.5	72 35.5	222 13.9	92 13.3	91 25.4	936 16.5
South region	382 14.5	32 16	29 14.3	136 8.5	91 13.2	15 4.2	685 12.1
Month							
April	65 2.5	40 20	1 0.5	42 2.6	155 22.4	1 0.3	304 5.3
May	397 15.1	99 49.5	11 5.4	223 13.9	377 54.5	18 5	1,125 19.8
June	1,075 40.9	44 22	100 49.3	735 45.9	117 16.9	180 50.3	2,251 39.6
July	1,093 41.6	17 8.5	91 44.8	600 37.5	43 6.2	159 44.4	2,003 35.2
Emergency stay prior to hospi	talization						
No	1,802 68.5	131 65.5	147 72.4	1,234 77.1	443 64	249 69.6	4,006 70.5
Yes	828 31.5	69 34.5	56 27.6	366 22.9	249 36	109 30.4	1,677 29.5
Charlson index							
0	2,416 91.9	190 95.0	190 93.6	1,497 93.6	650 93.9	336 93.9	5,279 92.9
1	125 4.8	7 3.5	10 4.9	79 4.9	31 4.5	18 5.0	270 4.8
2	66 2.5	3 1.5	2 1.0	16 1.0	7 1.0	3 0.8	97 1.7
3	9 0.3	0.0	1 0.5	5 0.3	0.0	0.0	15 0.3
4	9 0.3	0.0	0.0	1 0.1	4 0.6	1 0.3	15 0.3
5	1 0.0	0.0	0.0	1 0.1	0.0	0.0	2 0.04
6	3 0.1	0.0	0.0	0.0	0.0	0.0	3 0.05
7	1 0.0	0.0	0.0	1 0.1	0.0	0.0	2 0.04

19

Obesity														
No	2,522		188			94.1	1,534			93.6		96.4	5,428	
Yes	108	4.1	12	6	12	5.9	66	4.1	44	6.4	13	3.6	255	4.5
Uncomplicated/complicated hypertension														
No	2,220	84.4	173	86.5	153	75.4	1,364	85.3	587	84.8	293	81.8	4,790	84.3
Yes	410	15.6	27	13.5	50	24.6	236	14.8	105	15.2	65	18.2	893	15.7
Cardiovascular disease														
No	2,593	98.6	199	99.5	200	98.5	1,584	99		99.6	354	98.9	5,619	98.9
Yes	37	1.4	1	0.5	3	1.5	16	1	3	0.4	4	1.1	64	1.1
Neurological disorder														
No	2,582	98.2	198	99	195	96.1	1,586	99.1	689	99.6	354	98.9	5,604	98.6
Yes	48	1.8	2	1	8	3.9	14	0.9	3	0.4	4	1.1	79	1.4
Chronic lung disease														
No	2,594	98.6	196		199	98	1,572			97.7		97.5	5,586	
Yes	36	1.4	4	2	4	2	28	1.8	16	2.3	9	2.5	97	1.7
Mil/severe liver disease														
No	2,604	99	199	99.5	201	99	1,595	99.7	689	99.6	356	99.4	5,644	99.3
Yes	26	1	1	0.5	2	1	5	0.3	3	0.4	2	0.6	39	0.7
Diabetes mellitus														
No	2,335	88.8	177	88.5	168	82.8	1,397	87.3	613	88.6	314	87.7	5,004	88.1
Yes	295	11.2	23	11.5	35	17.2	203	12.7	79	11.4	44	12.3	679	11.9
Chronic kidney disease														
No	2,498	95	192	96	190	93.6	1,549	96.8	674	97.4	349	97.5	5,452	95.9
Yes	132	5	8	4	13	6.4	51	3.2	18	2.6	9	2.5	231	4.1
Cancer														
No	2,589	98.4	198	99	201	99	1,588	99.3	690	99.7	356	99.4	5,622	98.9
Yes	41	1.6	2	1	2	1	12	0.8	2	0.3	2	0.6	61	1.1
Metabolic disease														
No	2,627	99.9	200	100	203	100	1,599	99.9	692	100	358	100	5,679	99.9
Yes	3	0.1	0	0	0	0	1	0.1	0	0	0	0	4	0.1
Peptic ulcer disease														
No	2,628	99.9	200	100	203	100	1,600	100	692	100	358	100	5,681	100
Yes	2	0.1	0	0	0	0	0	0	0	0	0	0	2	0
HIV														
No	2,621	99.7	200	100	203	100	1,599	99.9	688	99.4	357	99.7	5,668	99.7
	,						, -						, -	

Yes	9	0.3	0	0	0	0	1	0.1	4	0.6	1	0.3	15	0.3
Antibiotics use first 48 hours after admission														
No	2,303	87.6	180	90	172	84.7	1,357	84.8	604	87.4	316	88.5	4,932	86.8
Yes	325	12.4	20	10	31	15.3	243	15.2	87	12.6	41	11.5	747	13.2
Treatment with ACEI or ARB														
No	2,468	93.9	184	92	196	96.6	1,548	96.8	670	97	341	95.5	5,407	95.2
Yes	160	6.1	16	8	7	3.4	52	3.3	21	3	16	4.5	272	4.8
Corticoid use during first 48 hours	Corticoid use during first 48 hours													
No	2,399	91.2	182	91	188	92.6	1,455	90.9	641	92.6	341	95.3	5,206	91.6
Yes	231	8.8	18	9	15	7.4	145	9.1	51	7.4	17	4.7	477	8.4
Anticoagulation														
No	2,287	87	173	86.5	182	89.7	1,410	88.1	598	86.4	318	88.8	4,968	87.4
Yes	343	13	27	13.5	21	10.3	190	11.9	94	13.6	40	11.2	715	12.6
Pneumonia diagnosis at first 48 hours														
No	2,186	83.1	143	71.5	159	78.3	1,292	80.8	485	70.1	244	68.2	4,509	79.3
Yes	444	16.9	57	28.5	44	21.7	308	19.3	207	29.9	114	31.8	1,174	20.7

HCQ: Hydroxychloroquine or chloroquine. IVM: ivermectin. AZIT: azithromycin. AZIT + HCQ: azithromycin plus hydroxychloroquine. AZIT + IVM: azithromycin plus ivermectin. ACEI: angiotensin converting enzyme inhibitor. ARB: angiotensin receptor blocker. SD: standard deviation; %: Percentage of column.

Table 2. Primary and secondary outcomes in patients with COVID-19 assigned to treatment groups or standard care (control group)

Outcome	Standard of care	HCQ group	IVM group	AZIT group	HCQ+AZIT group	IVM+AZIT group
All-cause deaths						
Nº of events / Total	401/2630	49/200	47/203	325/1600	165/692	85/358
30-days Cumulative Incidence (%) *	42.6 (37.5-48.2)	49.7 (33.1-69.1)	51.4 (35.2-69.9)	50.3 (43.5-57.6)	48.7 (40.1-58.2)	47.2 (37.0-58.6)
uHR (95% CI) **	1.00 (Ref)	1.39 (0.94-2.05)	1.40 (0.94-2.08)	1.13 (0.94-1.37)	1.20 (0.95-1.53)	1.40 (1.03-1.90)
wHR (95% CI) ***	1.00 (Ref)	1.73 (0.94-3.17)	1.39 (0.88-2.22)	1.15 (0.94-1.40)	1.84 (1.12-3.02)	1.37 (0.91-2.05)
All-cause deaths and/or ICU transfer						
Nº of events / Total	652/2630	71/200	79/203	481/1600	237/692	122/358
30-days Cumulative Incidence (%) *	51.3 (45.1-57.9)	65.6 (43.8-86.1)	58.7 (42.5-75.5)	54.3 (47.2-61.8)	54.4 (47-62.2)	55.7 (45.9-66.0)
uHR (95% CI) **	1.00 (Ref)	1.29 (0.93-1.78)	1.57 (1.16-2.14)	1.06 (0.91-1.23)	1.13 (0.93-1.37)	1.24 (0.96-1.59)
wHR (95% CI) ***	1.00 (Ref)	1.55 (0.96-2.49)	1.58 (1.11-2.25)	1.08 (0.92-1.27)	1.49 (1.01-2.19)	1.28 (0.94-1.76)
All-cause deaths and/or oxygen prescr	ription					
Nº of events / Total	494/2630	59/200	52/203	414/1600	198/692	101/358
30-days Cumulative Incidence (%) *	48.5 (43.1-54.2)	55.2 (37.8-74.3)	58.7 (42-76.1)	57.8 (50.8-65)	54.3 (45.4-63.6)	51.7 (41.5-62.8)
uHR (95% CI) **	1.00 (Ref)	1.47 (1.03-2.10)	1.29 (0.88-1.88)	1.17 (0.98-1.40)	1.23 (0.98-1.53)	1.39 (1.04-1.85)
wHR (95% CI) ***	1.00 (Ref)	1.77 (1.01-3.11)	1.21 (0.77-1.90)	1.17 (0.97-1.41)	1.70 (1.07-2.69)	1.21 (0.82-1.80)

uHR = unweighted hazard ratio; wHR = weighted hazard ratio; 95% CI = 95% confidence interval.

<sup>\*</sup> Cumulative incidence and 95% confidence intervals were obtained by Kaplan Meier life table method to account by censors.

<sup>\*\*</sup> Unweighted hazard ratios and 95% confidence intervals

<sup>\*\*\*</sup> Weighted hazard ratios and 95% confidence intervals were obtained by inverse probability treatment weighting. A gradient boosting machine was trained to estimate each patient's probability of receiving treatments given their baseline probabilities. Baselines covariates used to train the GBM were age, sex, healthcare centre location, month, Charlson's index at hospital admission, comorbidities registered in the first 48 hours (myocardial infarct/chronic heart failure/peripheral vascular disease, stroke, chronic lung disease, mild/severe liver disease, uncomplicated/complicated diabetes mellitus, cancer, stroke/dementia/paralysis, chronic kidney disease, metabolic disease, peptic ulcer disease, HIV, uncomplicated/complicated hypertension), emergency care before admission, antibiotics (other than azithromycin) used in the first 48 hours, angiotensin-converting enzyme inhibitors/angiotensin-II receptor antagonists use, and pneumonia diagnosis in the first 48 hours.




Figure 2. Baseline covariates balance measured as standardized mean differences, before and after inverse probability of treatment weighting




Figure 3. Weighted Kaplan-Meier curves for survival between each group of treatment versus standard care (control group)

